Kimberly Chong

Array ( [id] => 14199461 [patent_doc_number] => 10266827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => Antisense oligonucleotides for inducing exon skipping and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/112453 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 24 [patent_no_of_words] => 18521 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17527062 [patent_doc_number] => 11299735 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Compositions and methods for detecting and treating insulin resistance [patent_app_type] => utility [patent_app_number] => 16/475549 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 50 [patent_no_of_words] => 18308 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733981 [patent_doc_number] => 20180371458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/112371 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072881 [patent_doc_number] => 20190085328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA [patent_app_type] => utility [patent_app_number] => 16/106997 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16106997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185795 [patent_doc_number] => 20190112602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE [patent_app_type] => utility [patent_app_number] => 16/105926 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102987 [patent_doc_number] => 20190093169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => BIOMARKERS AND TREATMENTS FOR HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/105472 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15990401 [patent_doc_number] => 20200171071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => MODULATION OF THE NOTCH SIGNALING PATHWAY FOR TREATMENT OF RESPIRATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 16/638018 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20158429 [patent_doc_number] => 12385041 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Conditional-siRNAS and uses thereof in treating cardiac hypertrophy [patent_app_type] => utility [patent_app_number] => 16/638107 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 230 [patent_figures_cnt] => 90 [patent_no_of_words] => 14469 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206898 [patent_doc_number] => 20200239888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF PROTEIN AGGREGATION [patent_app_type] => utility [patent_app_number] => 16/636485 [patent_app_country] => US [patent_app_date] => 2018-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13987197 [patent_doc_number] => 20190062756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => COMPOUNDS FOR MODULATING FC-EPSILON-RI-BETA EXPRESSION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/052130 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16052130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14567459 [patent_doc_number] => 20190211336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field [patent_app_type] => utility [patent_app_number] => 16/046389 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16177228 [patent_doc_number] => 20200224196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => SINGLE-STRANDED OLIGONUCLEOTIDE [patent_app_type] => utility [patent_app_number] => 16/633532 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 485 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16633532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452910 [patent_doc_number] => 20200362336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => ANTISENSE OLIGONUCLEOTIDES THAT BIND TO EXON 51 OF HUMAN DYSTROPHIN PRE-MRNA [patent_app_type] => utility [patent_app_number] => 16/632827 [patent_app_country] => US [patent_app_date] => 2018-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132739 [patent_doc_number] => 20190100759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 16/037726 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793921 [patent_doc_number] => 20190010499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => METHODS FOR IMPROVED APTAMER SELECTION [patent_app_type] => utility [patent_app_number] => 16/037961 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132739 [patent_doc_number] => 20190100759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 16/037726 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13508301 [patent_doc_number] => 20180305693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => TREATMENT OF DOWN SYNDROME GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A DOWN SYNDROME GENE [patent_app_type] => utility [patent_app_number] => 16/026359 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15994065 [patent_doc_number] => 20200172903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/616743 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14199465 [patent_doc_number] => 10266829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => Interfering RNA molecules [patent_app_type] => utility [patent_app_number] => 16/013776 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 48 [patent_no_of_words] => 18583 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16013776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824602 [patent_doc_number] => 20210139895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/623249 [patent_app_country] => US [patent_app_date] => 2018-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623249 [rel_patent_id] =>[rel_patent_doc_number] =>)